Wegovy provider-guided follow-up in NYC

The prescriber should set follow-up timing for initiation, escalation and ongoing care. Review sooner for troublesome symptoms, glucose concerns or a refill interruption. A stable treatment plan may use a different interval from a new start; confirm the next appointment and how to contact the team between visits.

Review weight trend, appetite, food and fluid intake, bowel symptoms, and treatment tolerability. Check glucose and adjust other diabetes medicines with the prescriber when relevant. Agree on how to contact the team between visits and what to do if a refill is delayed. Continued treatment depends on benefit, safety, access, and your goals.

Tell the prescriber about nausea or constipation, particularly after a dose change. Discuss tolerated food and fluid intake and do not increase the dose until the plan has been reviewed. Review fluid intake, tolerated fiber, activity, other medicines, and whether symptoms followed a dose change. Contact the prescriber for persistent constipation or before increasing treatment. Severe pain, vomiting, marked swelling, or inability to pass stool or gas needs prompt assessment.

Contact the prescribing team before you run out. Review the exact strength, last dose, expected delay, and safe alternatives. A prolonged gap may need a restart plan. Do not substitute a different product, overlap medicines, or restart your previous high dose yourself.

Yes. Fatigue is listed among common Wegovy adverse reactions, but new tiredness can also need assessment for another cause. Tell the prescriber if it persists, worsens or affects normal activity. Vomiting or diarrhea with dehydration and low blood sugar, especially with insulin or a sulfonylurea, need particular attention. Check glucose as directed if you have symptoms of low blood sugar. Fainting, confusion or inability to keep fluids down needs urgent medical assessment.

Wegovy reduced weight more than placebo in clinical trials when used with a reduced-calorie diet and increased physical activity. Results differ by formulation, dose, trial population and whether treatment continued. Approval and average trial results do not guarantee a particular amount of weight loss. Review your weight trend, nutrition, tolerability and treatment duration with the prescriber to decide whether the benefit justifies continuing.

It depends on the formulation, indication and tolerability. For weight management with the injection, 1.7 or 2.4 mg weekly are labeled maintenance options, with 2.4 mg recommended. Lower 0.25, 0.5 and 1 mg stages are escalation doses. The prescriber may delay an increase for tolerability rather than treating a starter dose as a permanent plan. Wegovy tablets have a separate 25 mg daily maintenance dose. Their starter strengths are not interchangeable with injection doses. Discuss persistent side effects and treatment response before changing the schedule.

Some nausea, vomiting or diarrhea may ease as treatment continues, but there is no guaranteed time for every symptom to stop. Symptoms can recur with dose increases. Tell the prescriber if they remain troublesome before increasing. Delaying escalation may be appropriate. Severe or persistent abdominal pain, repeated vomiting, dehydration or inability to drink needs prompt assessment. Do not wait for a severe problem to settle because stomach symptoms are common.

Wegovy is used for long-term weight management rather than a fixed short course. Treatment can continue while it provides benefit and remains tolerable and appropriate. Review response, nutrition, adverse effects and your ability to continue at follow-up visits. Weight can return after stopping, so discuss a continuing care plan before an interruption. There is no single duration that applies to everyone, and ongoing treatment is not a reason to ignore side effects.

There is no guaranteed day when appetite or weight will change. The injection is introduced through dose increases at four-week intervals, and the tablet uses successive 30-day stages. Starter dosing mainly allows a gradual introduction. Early experience does not establish the final response. Clinical weight outcomes are assessed over months. Follow weight trends and tolerability with the prescriber, and do not speed up dosing to force a faster result.